Ark Therapeutics gains wound care footwear
This article was originally published in Clinica
London, UK-based specialist healthcare group Ark Therapeutics has secured exclusive UK and international marketing rights to a medical footwear device developed by German surgical, trauma and woundcare specialist, Darco, for managing diabetic foot ulcers. Under the terms of the agreement, Darco will manufacture and supply the product to Ark, which, in turn, will be responsible for reimbursement and sales and marketing. The device, to be marketed as Kerraped, is already approved for reimbursement by the UK National Health Service.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.